Clinical trials: Schizophrenia and Disorders With Psychotic Features
Psychomotor Retardation, Psychomotor Slowing
Transcranial Magnetic Stimulation (TMS) for Motor Symptoms in Psychiatric Disorders
Psychomotor slowing may occur in major psychiatric disorders, such as major depressive disorders or schizophrenia spectrum disorders. It refers to slowing of fine motor skills, motor planning and gross motor behavior.
- Conditions
- Psychomotor Retardation, Psychomotor Slowing, Schizophrenia and Related Disorders, Major Depressive Disorder
- Trial name
- NCT03275766
- Testing
- DLPFC facilitatory, SMA inhibitory, SMA facilitatory
- Where
- Switzerland
- Volunteers
- 45 people
- Sponsor
- University of Bern
Schizophrenia, Psychotic Disorders
Bergen Psychosis Project 2 - The Best Intro Study
In the Bergen Psychosis Project 2 the antipsychotic drugs aripiprazole, amisulpride, and olanzapine will be compared head-to-head in patients with schizophrenia and related psychoses and followed for 12 months.
- Trial name
- BP2 (NCT01446328)
- Testing
- Amisulpride, Aripiprazole, Olanzapine
- Where
- 4 sites in Austria, Norway
- Volunteers
- 151 people
- Sponsor
- Haukeland University Hospital
Psychosis
Mechanisms of Cognitive Change
This study will determine whether targeted cognitive training, a low-cost and low-risk commercial cognitive remediation therapy, directly impacts therapeutic targets as well as secondary outcomes in college undergraduates.
- Trial name
- CTCS (NCT04103775)
- Testing
- Cognitive Remediation, Active Control
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Colorado State University
Psychosis
mHealth for Psychosis Help-seeking
The proposed study research project aims to develop and test a mobile health intervention designed to improve the wellness of young people at risk for psychosis and facilitate users' engagement with treatment and thus reduce…
- Trial name
- NCT05905601
- Testing
- NORTH "Full", NORTH "Lite"
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Washington
Schizophrenia, Moral Status
Effects of Integrated Moral Reasoning Development Intervention for Management of Violence in Schizophrenia
Moral cognition is an important and multidimensional, but often overlooked, determinant of violence. Very few interventions have systematically examined the role of moral reasoning, anger management and problem-solving together…
- Conditions
- Schizophrenia, Moral Status, Violence
- Trial name
- NCT05207319
- Testing
- integrated Moral Reasoning Development Intervention (MRDI)
- Where
- Taiwan
- Volunteers
- 43 people
- Sponsor
- I-Shou University
Schizophrenia, Diminished P50 Sensory Gating
Phosphatidylcholine Supplementation in Infants
Sensory gating is defined as the automatic process of inhibiting brain response to repeated auditory sounds. Infants who brains respond similarly to two identical sounds presented about 1/2 second apart are more likely to have…
- Trial name
- NCT01905605
- Testing
- phosphatidylcholine supplementation
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Psychosis, Schizophrenia Disorders
DIALOG: Understanding Disorganisation: A Language-focused Global Initiative in Psychosis
Disorganized speech, language and communication, also called 'formal thought disorder,' is a key part of severe mental illnesses like psychosis and mood disorders.
- Conditions
- Psychosis, Schizophrenia Disorders, Bipolar Affective Disorder, Depressive Disorder
- Trial name
- DIALOG (NCT06978465)
- Where
- Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Schizophrenia
Effects of Eszopiclone on Sleep and Memory in Schizophrenia
The investigators will test the hypothesis that the sleep medication, eszopiclone, can normalize brain activity during sleep and improve memory in patients with schizophrenia.
- Trial name
- NCT01641900
- Testing
- eszopiclone
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizoaffective Disorder
Sodium Nitroprusside in Early Course Schizophrenia
Peripheral inflammation and microvascular dysfunction are central to the pathophysiology of schizophrenia (SZ). Retinal imaging allows for the accurate quantitative assessment of the condition of retinal microvessels, and early…
- Trial name
- NCT04986072
- Testing
- Sodium Nitroprusside, 5% Dextrose solution
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Beth Israel Deaconess Medical Center
Schizophrenia, Psychosis
Social Cognitive Training for Psychosis: Treatment Development
The primary aim of this proposal is to develop, refine, manualize and assess the feasibility and preliminary efficacy of a brief, narrowly-focused social cognitive intervention for individuals with psychosis.
- Trial name
- NCT01579422
- Testing
- social cognitive training
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Yale University
Schizophrenia
Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment
The objective of this study is to evaluate under routine clinical setting the efficacy and remission status from treatment of 2nd-generation antipsychotic in patients who is upon acute episode or not achieving remission under…
- Trial name
- QTP NIS (NCT00809731)
- Where
- 17 sites in Taiwan
- Volunteers
- 490 people
- Sponsor
- AstraZeneca
Schizophrenia
A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.
The purpose of this study is to examine treatment practices of adult schizophrenia patients by their own doctors, and to assess patient outcomes when treated with long-acting risperidone injection over a two-year period of…
- Trial name
- NCT00261430
- Testing
- GAIN Acceptance Approach
- Volunteers
- 650 people
- Sponsor
- Janssen, LP
Schizophrenia
Low and High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Resistant Auditory Hallucination in Schizophrenia
Auditory Hallucinations (AH) are experienced by 50 to 70% of subjects with schizophrenia. Almost a quarter of patients are medication resistant to such symptoms.
- Trial name
- rTMS (NCT02175251)
- Testing
- high frequency (20Hz), low frequency (1Hz)
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Schizophrenia
Tolerability of MDMA in Schizophrenia
Impaired social motivation, or "asociality," is a negative symptom of schizophrenia (SCZ) and a cause of significant functional impairment in the illness.
- Trial name
- TMS (NCT05770375)
- Testing
- MDMA 40mg, MDMA 80mg, MDMA 120mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Anya Bershad, MD, PhD
Schizophrenia, Renal Impairment
A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal Function
The purpose of this study is to evaluate the pharmacokinetics of a single oral dose of 3 mg extended release paliperidone (ER OROSÃ' paliperidone) in patients with varying degrees of renal impairment (mild, moderate, and severe)…
- Trial name
- NCT00791401
- Testing
- ER OROS Paliperidone
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses
To evaluate the pharmacokinetics (PK), tolerability, and safety of brexpiprazole QW formulation administered as single and multiple doses in patients with schizophrenia.
- Trial name
- NCT04118127
- Testing
- 2mg conventional tablet, once-weekly tablets
- Where
- Japan
- Volunteers
- 73 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia, Schizoaffective Disorder
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
Treatment of schizophrenia currently includes antipsychotic medications and cognitive therapies which improve some symptoms, but do not sufficiently restore cognitive functioning or reduce psychosocial disability.
- Trial name
- NCT04857983
- Testing
- Memantine
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of California, San Diego
Schizophrenia, Schizoaffective Disorder
Optimizing Response in Psychosis Study
The purpose of this project is to evaluate the efficacy of long-acting risperidone for patients with first episode schizophrenia spectrum who did not improve sufficiently with the first antipsychotic medication they tried during…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder Not Otherwise Specified
- Trial name
- ORP (NCT00314327)
- Testing
- long-acting injectable risperidone
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Northwell Health
Schizophrenia
Paliperidone Palmitate Flexible Dosing in Schizophrenia
This study explores the tolerability, safety and efficacy (i.e. how well the drug works) of flexibly dosed paliperidone palmitate in the treatment of schizophrenia in patients previously unsuccessfully treated with other oral or…
- Trial name
- PALMFlexS (NCT01281527)
- Testing
- Paliperidone Palmitate
- Where
- 127 sites in Austria, Belgium and 18 more
- Volunteers
- 1,044 people
- Sponsor
- Janssen-Cilag International NV
Schizoaffective Disorder, Schizophrenia
Obstructive Sleep Apnea Treatment in Serious Mental Illness
Serious mental illnesses (SMI) like schizophrenia and bipolar disorder are two of the most disabling and costly chronic illnesses worldwide.
- Conditions
- Schizoaffective Disorder, Schizophrenia, Bipolar Disorder, Obstructive Sleep Apnea of Adult
- Trial name
- NCT05457127
- Testing
- Automatic Positive Airway Pressure (APAP)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.